Literature DB >> 119271

Metrazol-produced impairment of passive avoidance retention specifically antagonized by anti-petit mal drugs.

G Clincke, A Wauquier.   

Abstract

In a single session, naive female 250-g Wistar rats were trained to remain for 3 min on a platform located above an electrifiable grid. During training, animals were shocked (4 mA) after they stepped down. Retention of the step-down avoidance was tested 24 h later in rats treated SC 30 min before the session with saline or a subconvulsive dose of metrazol (40 mg/kg). During the retention test no shock was delivered. The latency to step down and the time on the grid were recorded. The metrazol rats significantly failed to retain the avoidance task. Groups of six rats per dose were trained and 24 h later pretreated, 5 min before metrazol, with an IP injection of the following antiepileptics (dose range in mg/kg): Ethosuximide (20--320); trimethadione (20--320); clonazepam (0.04--0.63); sodium valproate (20--320); carbamazepine (1.25--20); phenobarbital (5--80); or diphenylhydantoin (5--80); or high dose of haloperidol (0.16) and amphetamine (0.63). Only ethosuximide, trimethadione, and clonazepam significantly increased the latency to step down and significantly shortened the time on the grid. Sodium valproate only shortened the time spent on the grid. The results suggest that only anti-petit mal drugs antagonize the retention impairment of passive avoidance produced by metrazol.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 119271     DOI: 10.1007/bf00428313

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  9 in total

1.  State-dependent learning produced by Metrazol.

Authors:  P Kurtz; T Palfai
Journal:  Physiol Behav       Date:  1973-01

2.  Antagonism of maximal metrazol seizures in rats and its relevance to an experimental classification of antiepileptic drugs.

Authors:  L K Desmedt; C J Niemegeers; P J Lewi; P A Janssen
Journal:  Arzneimittelforschung       Date:  1976

3.  Antiepileptic drug development: II. Anticonvulsant drug screening.

Authors:  R L Krall; J K Penry; B G White; H J Kupferberg; E A Swinyard
Journal:  Epilepsia       Date:  1978-08       Impact factor: 5.864

4.  Memory impairment in epileptic patients: selective effects of phenobarbital concentration.

Authors:  C M MacLeod; A S Dekabian; E Hunt
Journal:  Science       Date:  1978-12-08       Impact factor: 47.728

Review 5.  Benzodiazepines in the treatment of epilepsy. A review.

Authors:  T R Browne; J K Penry
Journal:  Epilepsia       Date:  1973-09       Impact factor: 5.864

6.  Clinical experience with clonazepam (Rivotril) in the treatment of epilepsies in infancy and childhood.

Authors:  D Martin; H R Hirt
Journal:  Neuropadiatrie       Date:  1973-07

7.  Clonazepam: a review of its pharmacological properties and therapeutic efficacy in epilepsy.

Authors:  R M Pinder; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1976-11       Impact factor: 9.546

Review 8.  Sodium valproate: a review of its pharmacological properties and therapeutic efficacy in epilepsy.

Authors:  R M Pinder; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1977-02       Impact factor: 9.546

9.  Sodium valproate in treatment of epilepsy.

Authors:  P M Jeavons; J E Clark
Journal:  Br Med J       Date:  1974-06-15
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.